Cimetidine, widely used for peptic ulcer disease, blocks type 2 histamine receptors present on immune cells, including T cells, B cells, and monocytes. As an earlier published study showed evidence of increases in CD4 cell counts due to this drug, we conducted a randomized, placebocontrolled, 8-week trial of oral cimetidine (400 mg po t.i.d.) in a study involving 182 patients infected with human immunodeficiency virus (HIV). Overall, cimetidine-treated patients had a decline in CD4+ cell counts that was no different from the decline for placebo-treated persons, neither during the first 8 weeks of the trial (mean drop, 7.1% [standard error, 12.1 - 
liminary reports that patients who began receiving cimetidine had substantially and significantly increased CD4 + cell counts [15] but that a closely related compound, ranitidine (Zantac; Glaxo/Warner Wellcome, Morris Plains, NJ), improves cellular immune function without influencing CD4 + cell counts [3] . Antiretroviral therapies that increase CD4 + cell counts or induce declines in p24 antigen levels are linked to measurable clinical benefit [16] [17] [18] . Therefore, we designed an 8-week randomized, double-blind, placebo-controlled, multisite trial to evaluate the impact of cimetidine on CD4 + and CD8 + lymphocyte subsets and p24 antigen levels in HIV-infected persons.
Methods
Study-eligibility requirements for the HIV-infected participants were an absolute neutrophil count of >750/mm 3 and a transaminase value of <5 times the upper limit of the normal test value. We excluded persons who (1) had active opportunistic infection or cancer; (2) were pregnant; (3) were intolerant of cimetidine; or (4) were currently using warfarin or another H2 receptor blocker. Use of an antiretroviral medication concurrently with the study drug was acceptable if such medication had been administered in a stable regimen for at least 2 months before enrollment.
Enrollment of Patients
Participants in the study were enrolled through a network of affiliated primary care clinicians at 31 community-based primary care sites, including 13 private offices, 7 health maintenance organization/case management settings, 6 hospital-linked clinics, and 5 community health centers.
Study Design and Procedures
One hundred eighty-two persons were randomized to receive oral cimetidine (400 mg t.i.d.) or placebo for 8 weeks. After week 8, all participants were crossed over to an open-label cimetidine regimen (400 mg t.i.d.) for an additional 8 weeks; this provided access to study medication for all participants and an opportunity to explore potential effects in the placebo group. Patients were assigned to a given stratum on the basis of a CD4 cell count determined within 3 months prior to enrollment (see below). In addition to the screening and enrollment visits, study visits occurred every 4 weeks until the investigation was completed at week 16.
Two lymphocyte subset counts were determined at baseline (with use of Becton Dickinson [Cockeysville, MD] FACSCAN or Coulter [Hialeah, FL] EPICS flow cytometry, whole blood method) and during the study at weeks 4, 8, 12, and 16. The acid-dissociated p24 antigen level was determined at baseline and at week 8 with use of the EIA-based Coulter immune complex dissociation method for detection of p24 antigen (p24 Ag-AD, Coulter).
Participants were randomly assigned to receive cimetidine or placebo (with a 1:1 ratio) after they were stratified by CD4 cell count into one of two groups: <200/4 (low-count group) or _200/ii,L (high-count group). These strata were chosen to allow separate evaluation of cimetidine effects associated with varying degrees of immunocompetence.
The primary study endpoint was a change in CD4 + cell counts by treatment group (cimetidine vs. placebo) over the 8 weeks of the blinded study. To minimize test variability with regard to CD4+ cell counts, the average of two baseline CD4+ cell counts, determined within 1 month before the beginning of the study, was used as the initial value. Since the previously published data documented changes in CD4+ cell count after the use of cimetidine for 6 weeks, we reasoned that the average of the week 4 and week 8 values would document any true drug-induced change in the count and minimize the variability in CD4+ cell count analyses. Thus, the primary study endpoint is reported as the percentage of log-transformed CD4 cell count change, which is calculated as % CD4 change = fexp[log(CD4 follow-up) -log(CD4 baseline)] -1} X 100, where CD4 baseline is the mean of the two baseline values and CD4 follow-up is the mean of the week 4 and week 8 values. Multivariate regression measured the effect of potentially prognostic variables of log CD4 change. Data were analyzed with use of STATA software (Los Angeles).
Results
Of the 182 HIV-infected persons who were enrolled in the trial, data were available for 176 (97%) and 171 (94%) from at least 4 weeks and 8 weeks, respectively, of blinded, placebo- Overall, cimetidine was extremely well tolerated, with very few minor or serious adverse reactions. There were no deaths during the study. Of the 11 withdrawals of patients in the 8 weeks of blinded study, 6 were due to adverse events, including 2 in the placebo arm (pancreatitis in a patient receiving dideoxyinosine and Pneumocystis carinii pneumonia in another) and 4 in individuals taking cimetidine (described below); the remaining 5 withdrawals were voluntary.
During the open-label phase (second 8 weeks) of the study, three additional persons withdrew from the study because of possible adverse effects of cimetidine. During the entire course of the study, cimetidine was associated with the following adverse effects, leading to its withdrawal (n = 7): 2 cases of hives or rash, 2 cases of severe neutropenia, and 1 case of mild neutropenia. Two individuals receiving cimetidine withdrew because of concurrent illness (severe reaction to trimethoprimsulfamethoxazole in one and parasitic diarrhea in the other). Additional reasons for dropouts during weeks 8-16 of the study included noncompliance with the protocol and voluntary withdrawal (11 patients).
Demographic and laboratory characteristics of participants assigned by double-blinded randomization to receive cimetidine or placebo are presented in table 1. At enrollment, baseline characteristics in the two study groups were similar with regard to age, gender, race, and HIV risk group. The two groups' enrollment characteristics are further compared in table 2 on the basis of the two strata of CD4+ cell counts: <200/p,L or -200/iLL. In the low-count group, no significant differences were apparent in terms of the use of standard antiretroviral medications, a clinical diagnosis of AIDS (i.e., based on criteria of the Centers for Disease Control and Prevention for AIDS-defining opportunistic infection/malignancy), CD4 + and CD8 + cell counts and percentages, and results of p24 acid-dissociated antigen testing (quantitative and qualitative).
In the high-count group, persons assigned to placebo rather than cimetidine had significantly higher baseline CD4 + cell counts and percentages. No differences were apparent among persons in the high-count group in terms of clinical diagnosis of AIDS, use of antiretroviral therapy, CD8 + cell counts and percentages, and results of p24 acid-dissociated antigen testing (quantitative and qualitative). Differences in both qualitative and quantitative p24 antigen levels between placebo and cimetidine recipients in the low-count stratum were of borderline significance (.05 < P < .1).
Changes in OW Cell Counts During the Study
We compared the changes in CD4+ cell counts between the cimetidine and placebo groups in the first 8 weeks of study. Further evaluation of CD4 + cell count changes from baseline to weeks 4 and 8 was performed for each cell-count stratum . , no significant treatment effects were seen. Multivariate regression of changes in CD4+ cell count (the primary study endpoint) revealed no significant prognostic variables among age, previous antiviral therapy, clinical AIDS diagnosis, and CD4+ cell count stratum. Two sample tests found that only the baseline p24 antigen level (quantitative test value) was related to the CD4+ cell count change during the trial (P < .05).
The lack of effect of cimetidine treatment on CD4+ cell counts is also shown in the placebo group during the second 8-week period, in which the crossover to open-label cimetidine occurred. We found similar declines in the CD4 + cell count during the 8 weeks of blinded administration of placebo and cimetidine. In the placebo group, participants' CD4 + cell counts decreased a mean of 7.5% over the first 8 weeks and 8.1% during the 8 weeks they received cimetidine.
Parallel analyses of CD8 + cell counts revealed no evidence of a cimetidine treatment effect and no associations with age, gender, clinical AIDS diagnosis, use of antiretrovirals, CD4 + cell count, or p24 antigen positivity.
At a subset of sites, testing for acid-dissociated p24 antigen was performed. Overall, p24 antigen testing was completed on 72% of patients in the cimetidine arm and 75% of those in the placebo arm. Comparison of individuals on the basis of whether or not they underwent p24 antigen testing revealed no significant differences in terms of assignment to cimetidine or placebo, enrollment CD4 + cell values, use of antivirals, or clinical diagnosis of AIDS.
Qualitative and quantitative p24 antigen values in the treatment groups are presented in table 4. This table documents similar rates of p24 reactivity and values at baseline among the two study arms, stratified by cell-count group. No differences were apparent between treatment groups in terms of the percentage of patients reactive to p24 antigen or the p24 antigen concentrations in the reactive specimens at baseline vs. 8 weeks. Changes from baseline were evaluated among those with antigen levels of > 10 pg/mL at baseline; changes in the placebo group were somewhat significant (P < .1).
To explore potential treatment effects, declines in p24 antigen levels among individuals with detectable p24 antigen at enrollment are compared by treatment arm and CD4 + strata in table 4. Although this analysis was limited by the small numbers, in the overall group there were no significant differences in the frequency of declines in p24 antigen levels (cimetidine arm, 10% [2/21]; placebo arm, 18% [4/22] ). Subgroup evaluation of p24 antigen level changes associated with the CD4+ strata revealed no significant differences between the study arms. Nonparametric analyses of quantitative as well as qualitative changes in p24 antigen during the study revealed no difference between treatment groups, regardless of CD4 + stratum. 
Discussion
In this study we were unable to confirm the CD4+ cell count increases reported following a previous study of cimetidine's effects on patients with symptomatic HIV infection [15] . In addition, we did not find any significant antiviral effects of cimetidine, as measured by changes in p24 antigen.
To date, several studies using related H2 receptor blockers in HIV infection have produced contrasting results regarding the specific impact on quantitative T helper/suppressor cell subsets. In a double-blind placebo-controlled trial [3] , 18 asymptomatic HIV-infected persons with median CD4 + cell counts of 350/pL who were treated for 4 weeks with ranitidine showed significant immune-status improvement in terms of spontaneous and cytokine (rIL-2, rIFN-a)-stimulated natural killer cell activity, as well as T cell blastogenesis.
Of some concern, ranitidine induced significant increases in soluble IL-2 receptor that are associated with immune activation and that correlated to improvement in antibody response. As noted by the investigators, these changes are also seen in late-stage HIV infection and may be detrimental. There were no changes seen in the T helper/suppressor cell ratio or subsets [3] .
In contrast, Brockmeyer et al. [15] reported that open-label cimetidine (400 mg orally t.i.d.) given to 33 HIV-infected patients with HIV-related conditions (Walter Reed stages 3-5) increased OKT4 + helper cell counts and delayed-type hypersensitivity (DTH) skin test reactivity to recall antigens after 12 weeks of administration. These findings appeared partially reversible when reassessed 3 weeks following discontinuation of the regimen, and the values increased 6 weeks following its renewal. After this 21-week cycle, the mean OKT4 helper cell count/percentage increased from 385/21% to 693/34%. However, this open-label crossover study provided few details to evaluate the role of selection bias in enrollment, completeness of data, and the patient-dropout rate [15] .
Although our study differed in design from the German pilot study [15] , the results were fundamentally different. The pilot study enrolled 33 individuals with symptomatic HIV/AIDSrelated complex (Walter Reed stages 3-5). As noted, investigators documented significant improvements in most parameters tested, including clinical symptoms, CD4 + cell counts, reactivity to DTH skin test panels, and cell proliferation. Among the 182 participants in our study, the 120 whose CD4 + cell counts were --200///,L were similar to the patients of the pilot study [15] Despite these similarities in CD4+ cell values, patients in our study in this CD4 + cell-count range generally did not have symptomatic HIV infection, and many were receiving antiretroviral therapy. In a subset with similar characteristics, we still found no evidence of an effect. Furthermore, we observed a consistent lack of effect of cimetidine in analyses of these two measures (CD4 + cell count and percentage) in the treatment group and in multiple subgroups, including patients who were not receiving antiretrovirals.
Our study did not directly evaluate qualitative measures of CD4 + , CD8 + , and other immune cell function; therefore, we cannot address alternative hypotheses by which H2 receptor blockers may influence immune function. In addition, this study did not quantify the HIV-associated viral load with the most recent technology, which has become available since the study ended. Although p24 antigen correlates with more sensitive measures of active HIV replication such as plasma HIV-RNA levels, p24 antigen testing is less frequently reactive and may provide less complete information about HIV disease status [16 -20] .
Nonetheless, the consistent lack of a cimetidine treatment effect on study participants' CD4+ cell counts and p24 antigen levels provides a sound basis for a conclusion. These data also underscore the importance of independent investigation and controlled, blinded trials in the evaluation of any new therapy or new use of an established treatment after initial promising results are obtained.
This study documents that short-term use of cimetidine is safe for HIV-infected individuals but has no impact on important surrogate markers of HIV infection: CD4± and CD8 + cell counts and p24 antigen levels. Despite the limitations of these as surrogate markers, our results suggest that short-term use of cimetidine is unlikely to significantly impact the health and immune status of HIV-infected persons. Epidemiologic evaluation of existing databases may also be useful to consolidate safety data and explore other potential effects with longerterm use of cimetidine or other H2 receptor blockers by HIVinfected individuals.
